Yi‐Hsiang Huang
Ningbo University(CN)Jiangnan University(CN)National Yang Ming Chiao Tung University(TW)Kaohsiung Medical University(TW)National Chung Hsing University(TW)National Taiwan University(TW)The University of Western Australia(AU)Wenzhou Medical University(CN)Taipei Medical University Hospital(TW)Kaohsiung Medical University Chung-Ho Memorial Hospital(TW)Mackay Memorial Hospital(TW)Taipei Veterans General Hospital(TW)National Yang Ming University Hospital(TW)Ruian People's Hospital(CN)Zhujiang Hospital(CN)Hunan Communications Research Institute(CN)Institute of Statistical Science, Academia Sinica(TW)Tainan Municipal Hospital(TW)Honghu Hospital of Traditional Chinese Medicine(CN)Taipei Medical University(TW)Jining Medical University(CN)Southern Medical University(CN)National Defense Medical Center(TW)Hainan Medical University(CN)Beihang University(CN)Academia Sinica(TW)University of Hong Kong(HK)
Publications by Year
Research Areas
Liver Disease Diagnosis and Treatment, Hepatocellular Carcinoma Treatment and Prognosis, Hepatitis C virus research, Hepatitis B Virus Studies, Liver Disease and Transplantation
Most-Cited Works
- → Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial(2016)3,612 cited
- → NASH limits anti-tumour surveillance in immunotherapy-treated HCC(2021)1,186 cited
- → Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma(2009)434 cited
- → Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial(2018)350 cited
- → Randomized Controlled Trial of Entecavir Prophylaxis for Rituximab-Associated Hepatitis B Virus Reactivation in Patients With Lymphoma and Resolved Hepatitis B(2013)324 cited
- → A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements(2020)